Flag of the European Union EU Clinical Trials Register Help

Clinical trials for abbvie

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    547 result(s) found for: abbvie. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002491-26 Sponsor Protocol Number: M15-942 Start Date*: 2017-03-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experien...
    Medical condition: Chronic Hepatitis C Infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000221-39 Sponsor Protocol Number: M15-539 Start Date*: 2017-12-14
    Sponsor Name:AbbVie Inc
    Full Title: A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infectio...
    Medical condition: Severe Respiratory Syncytial Virus (RSV) Infection
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000452-24 Sponsor Protocol Number: M13-576 Start Date*: 2017-03-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinic...
    Medical condition: Hepatitis C Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002350-13 Sponsor Protocol Number: M15-410 Start Date*: 2016-01-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adu...
    Medical condition: Hepatitis C Virus (HCV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003191-50 Sponsor Protocol Number: M16-000 Start Date*: 2017-08-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10013099 Disease Crohns LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Ongoing) DK (Ongoing) DE (Ongoing) PT (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) LV (Ongoing) IE (Ongoing) BG (Ongoing) AT (Ongoing) PL (Ongoing) NL (Ongoing) EE (Ongoing) SE (Ongoing) ES (Ongoing) GR (Ongoing) NO (Ongoing) LT (Ongoing) BE (Ongoing) HR (Ongoing) FR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003073-26 Sponsor Protocol Number: M13-102 Start Date*: 2013-10-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) DE (Completed) ES (Completed) HU (Prematurely Ended) AT (Completed) BE (Completed) DK (Completed) PT (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003046-87 Sponsor Protocol Number: M15-997 Start Date*: 2017-03-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A multicenter, open Label study to assess the safety and efficacy of rIsankizuMab for MaInTenance in moderate to severe pLaquE type pSoriaSis (LIMMITLESS)
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) BE (Completed) DE (Completed) FI (Completed) CZ (Completed) PL (Completed) PT (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000641-31 Sponsor Protocol Number: M14-234 Start Date*: 2016-09-20
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) FI (Completed) HU (Completed) CZ (Completed) SE (Completed) PL (Completed) IE (Completed) PT (Completed) DE (Completed) LV (Completed) LT (Completed) AT (Completed) GR (Completed) BE (Completed) EE (Completed) NO (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001240-35 Sponsor Protocol Number: M14-433 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DE (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) NL (Completed) PL (Completed) DK (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) HR (Completed) SI (Completed) FR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-000674-38 Sponsor Protocol Number: M14-533 Start Date*: 2016-09-20
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC)
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) PL (Ongoing) SE (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) LV (Ongoing) GR (Trial now transitioned) EE (Ongoing) IE (Trial now transitioned) HU (Ongoing) PT (Trial now transitioned) LT (Trial now transitioned) BE (Ongoing) NO (Trial now transitioned) ES (Ongoing) HR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003503-64 Sponsor Protocol Number: M16-298 Start Date*: 2017-06-12
    Sponsor Name:Abbvie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell L...
    Medical condition: Extensive Stage Small Cell Lung Cancer (ED SCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) AT (Completed) DK (Prematurely Ended) FI (Completed) IE (Completed) GB (Completed) SE (Completed) DE (Prematurely Ended) NL (Completed) LV (Prematurely Ended) PT (Prematurely Ended) HU (Completed) GR (Completed) PL (Completed) ES (Prematurely Ended) CZ (Completed) BG (Prematurely Ended) LT (Completed) BE (Completed) HR (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2016-000642-62 Sponsor Protocol Number: M14-675 Start Date*: 2019-06-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: M14-675, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulc...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) LV (Completed) PT (Completed) FI (Completed) DE (Completed) GR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) CZ (Completed) LT (Completed) IE (Completed) HU (Completed) ES (Completed) SK (Completed) PL (Completed) FR (Completed) HR (Completed) NO (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001226-18 Sponsor Protocol Number: M14-431 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DK (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) DE (Completed) PL (Completed) CZ (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) SI (Completed) HR (Ongoing) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001225-41 Sponsor Protocol Number: M14-430 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comp...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) DE (Ongoing) SE (Trial now transitioned) LV (Ongoing) GB (GB - no longer in EU/EEA) PT (Ongoing) FR (Trial now transitioned) HU (Ongoing) NL (Trial now transitioned) IE (Completed) LT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) BG (Completed) BE (Trial now transitioned) SI (Completed) HR (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003669-87 Sponsor Protocol Number: M14-064 Start Date*: 2018-03-19
    Sponsor Name:Abbvie Deutschland GmbH & Co. KG
    Full Title: Phase 2 Study Comparing Efficacy and Safety of ABT-165 and FOLFIRI vs Bevacizumab and FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab
    Medical condition: metastatic adenocarcinoma of the colon or rectum previously treated with a regimen containing fluoropyrimidine/oxaliplatin and bevacizumab
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000240-22 Sponsor Protocol Number: M21-310 Start Date*: 2021-11-24
    Sponsor Name:AbbVie
    Full Title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Pla...
    Medical condition: Moderate and severe platysma prominence
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005398-18 Sponsor Protocol Number: W15-679 Start Date*: 2016-07-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Treating patients with early axial spondyloarthritis to target – a 1 year randomized controlled study taking an intense treatment approach versus routine treatment (STRIKE)
    Medical condition: Axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003753-29 Sponsor Protocol Number: M19-148 Start Date*: 2020-05-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke
    Medical condition: Acute Ischemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003752-36 Sponsor Protocol Number: M16-077 Start Date*: 2020-05-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury
    Medical condition: Spinal cord injury (SCI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10041552 Spinal cord injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003053-21 Sponsor Protocol Number: M16-560 Start Date*: 2019-06-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects with Moderate to Severe Rheumatoid Arth...
    Medical condition: Moderate to Severe Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 19:38:14 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA